Core Insights - ChengTian Technology has completed nearly 100 million RMB in Series B financing, led by Xi Chuang Investment, with the funds aimed at advancing embodied intelligent exoskeleton technology, developing new brain-machine products, expanding production bases, and global market outreach [3][4]. Group 1: Company Development - The company plans to launch the "EasyGo" exoskeleton product series in 2025, targeting elderly assistance and outdoor sports markets, utilizing lightweight carbon fiber materials and biomimetic structures, priced around 2500 RMB [4][7]. - ChengTian Technology's medical-grade products have served over 623,000 users, achieving a 98.7% accuracy rate in intention recognition through multi-modal biological signal fusion algorithms, and improving stroke patients' gait training efficiency by approximately 53% [7][8]. Group 2: Market Strategy - The company initially focused on medical-grade product development due to limited market awareness of exoskeleton robots, adopting a "B2B first, then B2C" approach [3][4]. - With advancements in embodied intelligence and general artificial intelligence, the company is now poised to expand from medical applications to consumer scenarios such as entertainment, mobility, and safety [4][5]. Group 3: Technological Advancements - ChengTian Technology is enhancing its rehabilitation solutions by integrating brain and spinal electrical signals into the recovery process, improving the efficacy of rehabilitation for spinal cord injury patients [5][8]. - The company aims to create a future where exoskeleton robots enhance human capabilities, promoting a symbiotic relationship between humans and machines rather than replacement [8].